Skip to content

    Recently Viewed

      Listening...

      The Road to a Vaccine: Experts weigh in on COVID-19 testing, vaccine trials, and more

      In Season 2 of The Road to a Vaccine, host Lisa Ling interviews scientists, global health leaders and other experts on the COVID-19 front lines to reveal the latest medical advances and collaborations to create a coronavirus vaccine—and hopefully a return to a world without the pandemic.


      In Episode 9 of The Road to a Vaccine, Lisa Ling speaks with Dr. Paul Stoffels on the latest coronavirus vaccine developments. Dr. Cato Laurencin discusses why it’s critical to have diversity in clinical trials. Plus, news on possible breakthroughs in COVID-19 diagnostic testing.
      RTAV: Season 2, Episode 9

      Lisa Ling

      Ling is the Executive Producer and host of This Is Life on CNN. She has also been a field correspondent for The Oprah Winfrey Show and a contributor to ABC News’ Nightline.

      Ayub Khattak

      Khattak is the CEO and co-founder of Cue Health Inc. He attended UCLA, where he earned a degree in mathematics while working in the university’s biochemistry laboratories. An avid innovator, Khattak holds over 100 patents worldwide related to inventions covering various aspects of molecular diagnostic systems.

      Cato T. Laurencin, M.D., Ph.D.

      Dr. Laurencin is University Professor at the University of Connecticut and Chief Executive Officer of the Connecticut Convergence Institute at the University of Connecticut. He is an expert in health disparities and is the Editor-in-Chief of the Journal of Racial and Ethnic Health Disparities, as well as a Core Faculty Member of the Africana Studies Institute at the University of Connecticut.

      Paul Stoffels, M.D.

      Dr. Stoffels is the Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. He spearheads the research and product pipeline by leading teams across all of the company’s sectors to set the company-wide innovation agenda, discovering and developing transformational healthcare solutions.

      4 ways Johnson & Johnson is cultivating outside-the-box innovations for COVID-19

      In addition to its own cadre of scientists hard at work fighting the pandemic, Johnson & Johnson also supports external researchers and entrepreneurs equally dedicated to finding solutions for the current health crisis. We take a look at some of this groundbreaking work happening across the globe—from San Francisco to Seoul.
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.